The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling

BACKGROUND: To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negative correlation between Wnt/ß‐catenin activation and immunogenicity and T‐cell infiltra...

Descripción completa

Detalles Bibliográficos
Autores principales: Krug, Sebastian, Mattheis, Laura, Haemmerle, Monika, Rosendahl, Jonas, Kleeff, Joerg, Michl, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955077/
https://www.ncbi.nlm.nih.gov/pubmed/34309225
http://dx.doi.org/10.1002/cnr2.1493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955077/
https://www.ncbi.nlm.nih.gov/pubmed/34309225
http://dx.doi.org/10.1002/cnr2.1493

Ejemplares similares